CRVS News and Press, Corvus Pharmaceuticals Inc. From 07/21/22

BURLINGAME, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the appointment of James Rosenbaum, M.D. as Senior Vice President of Research, effective immediately. His in...

Highlights new interim data from CPI-818 Phase 1/1b study in patients with relapsed T cell lymphomas Program covers scientific rationale, preclinical and clinical data for its three programs – mupadolimab (anti-CD73), ciforadenant (adenosine 2A receptor antagonist) and CP...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Corvus Pharmaceuticals press release (NASDAQ:CRVS): Q1 GAAP EPS of -$0.18. As of March 31, 2022, Corvus had cash, cash equivalents and marketable securities totaling $62.9 million For further details see: Corvus Pharmaceuticals GAAP EPS of -$0.18

BURLINGAME, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the quarter ended March 31, 2022. “We are adva...

BURLINGAME, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will host an R&D Symposium to provide an update on the Company’s three clinical programs...

Penny stocks are a great way to quickly make money in the stock market. Today we are looking at a handful that insiders including top management have decided to scoop up as the second quarter begins. The topic of stocks with insider activity has become a bigger point of focus for trader...

Corvus Pharmaceuticals, Inc. (CRVS) Q4 2021 Earnings Conference Call March 10, 2022 04:30 PM ET Company Participants Richard Miller - Co-Founder, President and CEO Leiv Lea - CFO Zack Kubow - Investor Relations, Real Chemistry Conference Call Participants Li Watsek - Cantor Fitzgerald Mara Go...

Corvus Pharmaceuticals press release (NASDAQ:CRVS): Q4 GAAP EPS of -$0.20 misses by $0.01. Q4 Cash and cash equivalents $69.45M For further details see: Corvus Pharmaceuticals GAAP EPS of -$0.20 misses by $0.01

BURLINGAME, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2021. ...